Valneva SE ADR(VALN) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -2.09 | Insider Own | 3.22% | Shs Outstand | 94.8M | Perf Week | 6.53% |
| Market Cap | 0.54B | Forward P/E | 8.96 | EPS next Y | 161.52% | Insider Trans | - | Shs Float | 92.1M | Perf Month | -7.68% |
| Enterprise Value | 0.64B | PEG | - | EPS next Q | -0.2 | Inst Own | 0.76% | Short Float | 0.21% | Perf Quarter | 14.89% |
| Income | -0.18B | P/S | 3.26 | EPS this Y | 34.96% | Inst Trans | 12.74% | Short Ratio | 2.52 | Perf Half Y | 6.13% |
| Sales | 0.17B | P/B | 5.84 | EPS next 5Y | - | ROA | -36.82% | Short Interest | 0.19M | Perf YTD | -35.26% |
| Book/sh | 0.98 | P/C | 3.91 | EPS past 3/5Y | 16% 0.9% | ROE | -118.01% | 52W High | -53.12% ($12.18) | Perf Year | -37.39% |
| Cash/sh | 1.46 | P/FCF | - | Sales past 3/5Y | -19.63% 9.4% | ROIC | -59.52% | 52W Low | 20.21% ($4.75) | Perf 3Y | -47.13% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -134.63% | Gross Margin | 16.4% | Volatility(W/M) | 2.53% 3.28% | Perf 5Y | -87.2% |
| Dividend TTM | - | EV/Sales | 3.87 | Sales Y/Y TTM | -21.91% | Oper. Margin | -86.72% | ATR (14) | 0.22 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 1.69 | EPS Q/Q | -136.61% | Profit Margin | -110.32% | RSI (14) | 47.86 | Recom | 1.44 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.16 | Sales Q/Q | -25.85% | SMA20 | 0.85% ($5.66) | Beta | 1.35 | Target Price | $12.28 |
| Payout | - | Debt/Eq | 2.59 | Earnings | 2026/8/13 | SMA50 | -8.08% ($6.21) | Rel Volume | 0.15 | Prev Close | $5.74 |
| Employees | 674 | LT Debt/Eq | 2.33 | EPS/Sales Surpr. | -82.17% -18.31% | SMA200 | -16.59% ($6.85) | Avg Volume(3M) | 0.08M | Price | $5.71 |
| IPO | 2021/5/6 | Option/Short | No/Yes | Trades | 101 | Volume | 11,519 | Change | -0.52% |
💉 Valneva is a France-based specialty biopharmaceutical company that develops and commercializes vaccines for infectious diseases, including the chikungunya vaccine (IXCHIQ) and the Japanese encephalitis vaccine (IXIARO). Leveraging its proprietary manufacturing platform and active clinical research, the company is pursuing pipeline collaborations with major pharmaceutical companies and building its own distribution network, steadily expanding its presence in the niche vaccine market.
Over the past 1 year, on the lower side
53% below its 1-year high.
Traded less than usual. That is 15% of its average volume.
VALN has a sound balance sheet but weak earning power
Of every $100 in sales, $86.72 is lost.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +35.0% this year.
Tap to view numbers
Relative to sales, it looks cheap
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $326. Peers typically go for $1,217.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -87.2%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 0.8%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
IDNA iShares Genomics Immunology and Healthcare ETF <0.01% 
FDTS First Trust Developed Markets ex-US Small Cap AlphaDEX Fund <0.01% 
GWX State Street SPDR S&P International Small Cap ETF <0.01% 
IEUS iShares MSCI Europe Small-Cap ETF <0.01% 
SCZ iShares MSCI EAFE Small-Cap ETF <0.01% It ranks #212 of 594 in the industry
Based on market cap of $543M.
FAQ
What kind of company is VALN?
VALN belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of VALN?
The market cap of VALN is approximately $543M, ranking 3,089 within its sector.
What is the 52-week high and low for VALN?
VALN has recorded a 52-week high of $12.18 and a low of $4.75.
